This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Mayo Foundation for Medical Education and Research, Osaka University. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2016
Title: Innovations in Cancer Treatment by Zhimin Li
Introduction
Zhimin Li is an accomplished inventor based in Jacksonville, FL (US). He has made significant contributions to the field of cancer treatment, particularly focusing on brain and nervous system cancers. His innovative work has led to the development of novel compounds that hold promise for improving patient outcomes.
Latest Patents
Zhimin Li holds a patent for "Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer." This patent relates to compounds and compositions that are useful for treating various cancers, including those affecting the brain and nervous system. The compounds include a compound of Formula I or a pharmaceutically acceptable salt thereof, which showcases the potential for targeted cancer therapies.
Career Highlights
Throughout his career, Zhimin Li has worked with prestigious institutions, including the Mayo Foundation for Medical Education and Research and Osaka University. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Zhimin Li has collaborated with notable colleagues such as Daisuke Shigeoka and Takuma Kamon. These partnerships have enhanced his research efforts and facilitated the development of innovative solutions for cancer treatment.
Conclusion
Zhimin Li's contributions to cancer research and treatment exemplify the impact of innovation in medicine. His patented compounds represent a significant advancement in the fight against brain cancer, showcasing the importance of continued research and collaboration in this critical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile